Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 17;4(1):14-18.
doi: 10.14744/hf.2022.2022.0038. eCollection 2023 Jan.

Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan

Ezgi Ersoy Yesil  1 , Yusuf Yilmaz  2 , Atakan Yesil  3 , Meral Mese  4 , Eda Kaya  5 , Elif Ari Bakir  4
Affiliations

Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan

Ezgi Ersoy Yesil et al. Hepatol Forum. .

Abstract

Background and aim: Metabolic dysfunction-associated fatty liver disease (MAFLD) is expected to be prevalent among kidney transplant recipients (KTRs). In this study, we evaluated the prevalence of MAFLD among KTRs, data that have not been investigated by any clinical study to date.

Materials and methods: We included a total of 52 KTRs and 53 age-, sex-, and BMI-matched individuals as the control group through prospective consecutive recruitment. We detected the presence of hepatic steatosis and liver fibrosis using the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) defined by FibroScan.

Results: Among the KTRs, 18 (34.6%) had metabolic syndrome. The prevalence of MAFLD among the KTRs and controls was 42.3% and 51.9%, respectively (p=0.375). The CAP and LSM values did not differ significantly between the KTRs and controls (p=0.222 and p=0.119). Among the KTRs, patients with MAFLD had significantly higher age, BMI, waist circumference, LDL, and total cholesterol levels (p<0.001, p=0.011, p=0.033, p=0.022, and p=0.029, respectively). In multivariable analysis, age was the only independent factor for MAFLD among the KTRs (OR: 1.120, 95% confidence interval (CI): 1.039-1.208).

Conclusion: MAFLD among KTRs did not show a significantly higher prevalence compared to the normal population. Further clinical studies with larger populations are needed.

Keywords: FibroScan; kidney transplant recipients; mafld.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

References

    1. Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–2682. - PubMed
    1. GBD Chronic Kidney Disease Collaboration Global, regional, and national burden of chronic kidney disease 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–733. - PMC - PubMed
    1. Ge X, Zheng L, Wang M, Du Y, Jiang J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional, and national levels, 1990-2017: a population-based observational study. BMJ Open. 2020;10(8):e036663. - PMC - PubMed
    1. Akahane T, Akahane M, Namisaki T, Kaji K, Moriya K, Kawaratani H, et al. Association between non-alcoholic fatty liver disease and chronic kidney disease: A cross-sectional study. J Clin Med. 2020;9(6):1635. - PMC - PubMed
    1. Kaps L, Labenz C, Galle PR, Weinmann-Menke J, Kostev K, Schattenberg JM. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterol J. 2020;8(8):942–948. - PMC - PubMed

LinkOut - more resources